The bill proposes significant changes to how health care plans in New Mexico manage prescription drug coverage, specifically in how they implement step therapy. By introducing a requirement for robust clinical review processes, it aims to prevent arbitrary denials of prescribed medications, particularly for conditions like autoimmune disorders, behavioral health issues, and others where immediate treatment is critical. If implemented, this legislation could enhance patient access to necessary medications, reducing the burden of having to try less effective or potentially harmful alternatives first.
Summary
House Bill 185, introduced in the New Mexico legislature, aims to establish clear guidelines for step therapy protocols related to prescription drug coverage. The bill requires that any health coverage plan which includes step therapy must develop clinical review criteria based on proven medical practices and studies. This legislative effort is focused on safeguarding patient treatment by ensuring that the drug sequences recommended are scientifically valid and fairly administered, thereby supporting patient rights over insurer protocols.
Contention
Notable points of contention surrounding HB185 include concerns expressed by insurers regarding the potential cost implications of mandating exceptions to step therapy protocols. While proponents argue that the bill will facilitate better healthcare outcomes and greater adherence to treatment plans, detractors fear that it could lead to increased healthcare costs due to higher medication use without prior trial of alternatives. Furthermore, the geographical and medical diversity of patients in New Mexico may present challenges in applying universal guidelines effectively, raising discussions about localized exceptions and individualized patient care.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.